Axsome Therapeutics, Inc.
NASDAQAxsome Therapeutics enters the final weeks of Q3 with a sharp divergence at its core: the Street is turning more constructive on the CNS drug developer, yet options traders have moved to their most defensive posture in months. The most telling move of the week came from the Street. Truist Securities raised its price target from $200 to $285 this morning, keeping a Buy rating — a…
Snapshot as of 7 Oct 2026
Axsome Therapeutics enters the final weeks of Q3 with a sharp divergence at its core: the Street is turning more constructive on the CNS drug developer, yet options traders have moved to their most defensive posture in…
Axsome Therapeutics enters the post-earnings week with a curious split: the Street is raising price targets while short sellers are quietly rebuilding positions, creating a tug-of-war around a stock that has already…
Axsome Therapeutics heads into its August 3 earnings print having shed 11% over the past month, with short sellers quietly adding pressure even as the analyst community stays firmly bullish. The most telling shift in…
Axsome Therapeutics heads into its August 3 earnings print with the most significant development since last week's note being a sharp reversal in short positioning — a story that materially changes the setup described…
Axsome Therapeutics enters the week of August earnings season with a rare alignment of bullish analyst momentum and quietly rising short interest — a combination that sets up an interesting tension heading into its…
AXSM enters the back half of June with an unusual tension: a fresh analyst upgrade pushing the price target ceiling higher while short sellers quietly rebuild positions at the fastest pace in months. TD Cowen's Joseph…
Axsome Therapeutics heads into its Q1 2026 earnings call on Friday, June 5 carrying two competing signals: a freshly settled SUNOSI patent dispute that removes a meaningful overhang, and a persistent pattern of insider…
Axsome Therapeutics heads into its May 4 Q1 report as one of the more bullishly positioned CNS names in the market, with the stock up 22% over the past month and analyst targets rising in lockstep. The analyst…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for AXSM — free to start on ORTEX.
Sign up for free →Open AXSM on ORTEX